1.Increased serum soluble-endoglin level and its clinical significance in antiphospholipid syndrome.
Ji LI ; Li ZHENG ; Lian Jie SHI ; Jing XU ; Jian Long SHU ; Xue Wu ZHANG
Journal of Peking University(Health Sciences) 2018;50(6):1027-1032
OBJECTIVE:
To detect the serum levels of soluble endothelial glycoprotein endoglin (s-Eng) in patients with antiphospholipid syndrome (APS) and to evaluate the correlation between s-Eng levels and clinical features and laboratory parameters.
METHODS:
The levels of serum s-Eng were measured by enzyme linked immunosorbent assay (ELISA) in 139 patients with APS, 44 patients with SLE but no APS, 37 patients with primary Sjögren's syndrome (pSS), 23 patients with Bechet's disease (BD), 22 patients with systemic sclerosis (SSc) and 22 persistent anticardiolipin antibody (aCL) positive individuals without SLE or APS (simply aCL positive group) and 87 health controls (HC) without any auto-immune diseases. These APS patients included 64 primary APS patients and 75 APS patients secondary to SLE.The correlation between the clinical data, laboratory parameters, and serum s-Eng levels were analyzed.Independent samples t test, paired t test, Chi-square Test, Mann-Whitney U test, Pearson's χ2 test were used for statistical analyses.
RESULTS:
(1) The serum levels of s-Eng were significantly higher in the patients with APS whether primary or secondary to SLE than in the health controls and simply aCL positive group and the patients with other autoimmune diseases, including SLE, pSS, BD and SSc (P<0.001). There was no significant difference in the serum s-Eng levels between simply aCL positive group and health controls [(5.17±2.00) mg/L vs. (5.04±1.11) mg/L, P>0.05]. (2) The best cut-off value for the diagnosis of APS was no less than 8.37 mg/L as mean ± 3SD value, with the sensitivity at 0.772 and the specificity at 0.928. The Youden index was 0.700. These results indicated good validity of s-Eng as a diagnostic marker for APS. (3) The proportions of artery thrombosis and pathological pregnancy were higher in the group of s-Eng-positive APS patients than that in s-Eng-negative group (46/81 vs. 19/58, 29/65 vs. 10/44, respectively, all P<0.05). The levels of PLT were lower in the group of s-Eng-positive APS patients (72.00×109/L vs. 119.00×109/L, P<0.001). (4) The proportions of the presence (93.83% vs. 37.93%, P<0.001) and titer (61.70 U/mL vs. 15.45 U/mL, P<0.001) of aCL were both higher in the group of s-Eng-positive APS patients than in s-Eng-negative group. The proportions of the presence (61.73% vs. 43.10%, P<0.05) and titer (33.48 U/mL vs.17.40 U/mL, P<0.05) of anti-β2-glycoprotein I antibody were both higher in the group of s-Eng-positive APS patients than in s-Eng-negative group too.
CONCLUSION
s-Eng serum levels were significantly increased in the patients with APS, and it may play a role as acomplementary serological marker for the diagnosis and risk prediction of APS.
Antibodies, Anticardiolipin
;
Antiphospholipid Syndrome/diagnosis*
;
Autoantibodies
;
Endoglin/blood*
;
Enzyme-Linked Immunosorbent Assay
;
Female
;
Humans
;
Pregnancy
2.Detection of six kinds of antiphospholipid antibodies in the serum of healthy volunteers.
Zhe GUO ; Yu-Ming ZHAO ; Ya-Kun WANG ; Sarabadani RAHIM ; Hong-Duo CHEN
Chinese Medical Sciences Journal 2004;19(2):149-149
Adult
;
Antibodies, Anticardiolipin
;
blood
;
Antibodies, Antiphospholipid
;
blood
;
Autoantibodies
;
blood
;
Female
;
Humans
;
Male
;
Middle Aged
;
Phosphatidic Acids
;
immunology
;
Phosphatidylcholines
;
immunology
;
Phosphatidylethanolamines
;
immunology
;
Phosphatidylinositols
;
immunology
;
Phosphatidylserines
;
immunology
;
Reference Values
5.Prevalence and Clinical Associations of Lupus Anticoagulant, Anticardiolipin Antibodies, and Anti-beta2-glycoprotein I Antibodies in Patients with Systemic Lupus Erythematosus.
Kwang Sook WOO ; Kyung Eun KIM ; Jeong Man KIM ; Jin Yeong HAN ; Won Tae CHUNG ; Kyeong Hee KIM
The Korean Journal of Laboratory Medicine 2010;30(1):38-44
BACKGROUND: The presence of antiphospholipid antibodies (aPLs) is associated with the clinical features of antiphospholipid syndrome (APS), which comprises venous and arterial thrombosis and pregnancy loss, and systemic lupus erythematosus (SLE). The prevalence of aPLs has been reported to be different in patient populations affected by either of these conditions. We performed a retrospective study to evaluate the prevalence and clinical associations of aPLs, including lupus anticoagulant (LAC), anticardiolipin (aCL), and anti-beta2-glycoprotein I antibodies (anti-beta2-GPI) in a cohort of Korean patients with SLE. METHODS: This study included samples from 88 SLE patients for whom aPL testing had been advised between June 2006 and July 2009 at the Dong-A University Hospital. Serum and plasma samples were tested for LAC, aCL (IgG, IgM), and anti-beta2-GPI (IgG, IgM) antibodies. Clinical data from patients were obtained from a review of medical records. RESULTS: LAC was the most common (34.1% of total patients, 30/88) antibody, followed by IgM aCL (31.8%, 28/88), IgG aCL (18.2%, 16/88), and IgM and IgG anti-beta2-GPI (both 5.7%, 5/88 each). Positivity for LAC was strongly associated with venous/arterial thrombosis (P=0.002). CONCLUSIONS: LAC was the most common antibody detected in Korean SLE patients and is shown to have a significant association with the presence of venous/arterial thrombosis. The measurement of LAC may be clinically useful in identifying patients with SLE who are at a high risk for venous/arterial thrombosis.
Adolescent
;
Adult
;
Antibodies, Anticardiolipin/*blood
;
Antibodies, Antiphospholipid/*blood
;
Cohort Studies
;
Female
;
Humans
;
Immunoglobulin G/blood
;
Immunoglobulin M/blood
;
Lupus Coagulation Inhibitor/*blood
;
Lupus Erythematosus, Systemic/epidemiology/*immunology
;
Male
;
Middle Aged
;
Pregnancy
;
Prevalence
;
Retrospective Studies
;
Risk Factors
;
Venous Thrombosis/epidemiology/immunology
6.A Case of Antiphospholipid Antibody Syndrome with AhA Nephropathy.
Jong Seo PARK ; Sung Jin KANG ; Yong An WOO ; Sung Sik RYU ; Gun Young HONG ; Soon Ho KIM ; Joong Kyu LIM ; Hyun Soon LEE
Korean Journal of Nephrology 1999;18(5):787-791
The antiphospholipid antibody syndrome is cha- racterized by antibodies directed against either phos-pholipids or plasma proteins bound to anionic phos- pholipids. These antibodies have been characterized by lupus anticoagulants and anticardiolipin antibodies. Patients with the antiphospholipid antibody syndrome may display a constellation of clinical features including venous and arterial thrombosis, recurrent fetal losses, and thrombocytopenia. Although the majority of patients reported have a thrombotic microangiopathy, some have also seen membranous nephopathy as well as IgA nephropathy in a patient with anti-phospholipid antibody syndrome accompanying glo-merulonephritis. Authors experienced a 37-year-old male patient who presented with generalized edema at the moment of follow-up for primary antiphos-pholipid syndrome accampanying systemic thrombotic events. Anticardiolipin antibody-IgM positivity was detected by seroligic test but no evidence for systemic lupus erythematosus was found. Kidney biopsy showed mesangial IgA deposition without th throm-botic microangiopathy of gomerular capillaries and was diagnosed finally as primary antiphospholipid syndrome with IgA nephropathy. Patient's symptom was relieved with steroids and anti platelete agents and now he is being follow-up to out patient department. This case suggests some possibility that anticardiolipin antibody may induce the IgA nephropathy. Therefore clinician should have concern about the relationship between antiphospholipid antibody and immune mediate glomerulonephritis.
Adult
;
Antibodies
;
Antibodies, Anticardiolipin
;
Antibodies, Antiphospholipid*
;
Anticoagulants
;
Antiphospholipid Syndrome*
;
Biopsy
;
Blood Platelets
;
Blood Proteins
;
Capillaries
;
Edema
;
Follow-Up Studies
;
Glomerulonephritis
;
Glomerulonephritis, IGA
;
Humans
;
Immunoglobulin A
;
Kidney
;
Lupus Erythematosus, Systemic
;
Male
;
Steroids
;
Thrombocytopenia
;
Thrombosis
;
Thrombotic Microangiopathies
7.The Role of Thrombophilia and Hypofibrinolysis in Legg-Calv-Perthes Disease.
Yong Chan HA ; Kyung Hoi KOO ; Hyung Bin PARK ; Sang Won CHO ; Yeon Cheon JUNG ; Hae Ryong SONG
The Journal of the Korean Orthopaedic Association 2000;35(6):833-836
PURPOSE: The object of present study was to investigate the relationship between LCPD and the abnormality of certain plasma proteins affecting clot mechanism and fibrinolysis in patients with LCP disease. MATERIALS AND METHODS: Twenty-five consecutive patients who had been diagnosed as LCP disease were matched with twenty-five controls for gender, age (2-year range) , and the time of presentation (1-year range) . There were twenty-three boys and two girls. The mean age of the children when the LCP disease was diagnosed was 6.7 years ( range, 2.1-12.8 years) , and the mean age at the time of the present study was 7.9 years ( range, 3.4 - 13 year) . Thrombotic disorders were investigated for protein C activity/antigenicity, protein S activity/antigenicity, antithrombin III, anticardiolipin antibody Ig G, anticardiolipin antibody Ig M, lupus antibody. Fibrinolytic disorders were investigated for tissue type plasminogen activator (t-PA) , plasminogen, plasminogen activator inhibitor-1 (PAI-1) , alpha 2 plasmin inhibitor, lipoprotein (a) . Wilcoxon rank sum test was used for the comparison. RESULTS: There was no significant difference in coagulation system and fibrinolytic system between patients and controls. CONCLUSION: Our results suggest that abnormality in coagulation and fibrinolytic system is not associated with Legg-Calv -Perthes disease.
alpha-2-Antiplasmin
;
Antibodies, Anticardiolipin
;
Antithrombin III
;
Blood Proteins
;
Child
;
Female
;
Fibrinolysis
;
Humans
;
Lipoprotein(a)
;
Plasminogen
;
Plasminogen Activators
;
Protein C
;
Protein S
;
Thrombophilia*
;
Tissue Plasminogen Activator
8.Echocardiographic changes and anticardiolipin antibodies in patients with systemic lupus erythematosus.
Sai-dan ZHANG ; Miao WU ; Feng CHEN ; Xiao-xia ZUO ; Jing ZHANG
Journal of Central South University(Medical Sciences) 2006;31(5):692-695
OBJECTIVE:
To analyze the echocardiographic abnormalities and the prevalence of anticardiolipin antibodies (aCL) in systemic lupus erythematosus (SLE) patients and to evaluate the relationship between aCL and cardiac valvular abnormalities in SLE patients.
METHODS:
Ninety SLE patients were performed M-mode, 2-dimensional and Doppler echocardiography and aCL IgG and IgM were measured by an enzyme-linked immunosorbent assay (ELISA). According to the abnormalities in the echocardiography, the patients were assigned into valvular abnormality group and non-valvular abnormality group. Chi-square method was used to compare the difference of aCL prevalence between the two groups.
RESULTS:
The prevalence of echocardiographic abnormalities was 53.33%, and valvular abnormality (38.89%) and pericardial effusion (34.44%) presented most frequently. The aCL prevalence was 32.56% in the 43 SLE patients. The prevalence of aCL in the valvular abnormality group was significantly higher than that in non-valvular abnormality group (52.94% vs 19.23%, P<0.05).
CONCLUSION
The incidence of echocardiographic abnormalities is high in SLE patients, most often in valves and pericardium. The aCL is probably related to valvular damage in SLE patients.
Adolescent
;
Adult
;
Antibodies, Anticardiolipin
;
blood
;
Echocardiography, Doppler
;
Female
;
Heart Valve Diseases
;
etiology
;
immunology
;
physiopathology
;
Humans
;
Lupus Erythematosus, Systemic
;
complications
;
immunology
;
physiopathology
;
Male
9.Etiologic characteristics and index pregnancy outcomes of recurrent pregnancy losses in Korean women.
Gi Su LEE ; Joon Cheol PARK ; Jeong Ho RHEE ; Jong In KIM
Obstetrics & Gynecology Science 2016;59(5):379-387
OBJECTIVE: The goal of this study was to evaluate the etiologies and clinical outcomes of Korean recurrent pregnancy loss (RPL) patients. And also, we investigated the differences between primary and secondary RPL patients, between two and three or more pregnancy losses. METHODS: One hundred seventy eight women diagnosed as RPL were enrolled. We performed chromosomal analysis, thyroid stimulating hormone, prolactin, blood glucose, plasminogen activator inhibitor-1, natural killer cell proportion, anticardiolipin antibodies, antiphospholipid antibodies, lupus anticoagulant, anti-β2glycoprotein-1 antibodies, antinuclear antibody, protein C, protein S, antithrombin III, homocysteine, MTFHR gene, factor V Leiden mutation, and hysterosalphingography/hysteroscopic evaluation. RESULTS: The mean age was 34.03±4.30 years, and mean number of miscarriages was 2.69±1.11 (range, 2 to 11). Anatomical cause (13.5%), chromosomal abnormalities (5.6%), and endocrine disorders (34.3%) were observed in RPL women. Elevated natural killer cell and antiphospholipid antibodies were observed in 43.3% and 7.3% each. Among of 178 women, 77 women were pregnant. After management of those women, live birth rate was 84.4% and mean gestational weeks was 37.63±5.12. Women with three or more RPL compared with women with two RPL had more common anatomical cause such as intrauterine adhesions and lower rates of spontaneous pregnancy. Compare with secondary RPL women, immunological abnormalities were more common in primary RPL. However, miscarriage rates were not different. CONCLUSION: Immunological factor including autoimmune and alloimmune disorders was most common etiology of RPL. Inherited thrombophilia showed different patterns with other ethnic countries. Miscarriage rates were not different between primary and secondary RPL, or between two and three or more miscarriages group.
Abortion, Spontaneous
;
Antibodies, Anticardiolipin
;
Antibodies, Antinuclear
;
Antibodies, Antiphospholipid
;
Antithrombin III
;
Blood Glucose
;
Chromosome Aberrations
;
Factor V
;
Female
;
Homocysteine
;
Humans
;
Killer Cells, Natural
;
Live Birth
;
Lupus Coagulation Inhibitor
;
Plasminogen Activators
;
Pregnancy
;
Pregnancy Outcome*
;
Pregnancy*
;
Prolactin
;
Protein C
;
Protein S
;
Thrombophilia
;
Thyrotropin
10.Etiologic characteristics and index pregnancy outcomes of recurrent pregnancy losses in Korean women.
Gi Su LEE ; Joon Cheol PARK ; Jeong Ho RHEE ; Jong In KIM
Obstetrics & Gynecology Science 2016;59(5):379-387
OBJECTIVE: The goal of this study was to evaluate the etiologies and clinical outcomes of Korean recurrent pregnancy loss (RPL) patients. And also, we investigated the differences between primary and secondary RPL patients, between two and three or more pregnancy losses. METHODS: One hundred seventy eight women diagnosed as RPL were enrolled. We performed chromosomal analysis, thyroid stimulating hormone, prolactin, blood glucose, plasminogen activator inhibitor-1, natural killer cell proportion, anticardiolipin antibodies, antiphospholipid antibodies, lupus anticoagulant, anti-β2glycoprotein-1 antibodies, antinuclear antibody, protein C, protein S, antithrombin III, homocysteine, MTFHR gene, factor V Leiden mutation, and hysterosalphingography/hysteroscopic evaluation. RESULTS: The mean age was 34.03±4.30 years, and mean number of miscarriages was 2.69±1.11 (range, 2 to 11). Anatomical cause (13.5%), chromosomal abnormalities (5.6%), and endocrine disorders (34.3%) were observed in RPL women. Elevated natural killer cell and antiphospholipid antibodies were observed in 43.3% and 7.3% each. Among of 178 women, 77 women were pregnant. After management of those women, live birth rate was 84.4% and mean gestational weeks was 37.63±5.12. Women with three or more RPL compared with women with two RPL had more common anatomical cause such as intrauterine adhesions and lower rates of spontaneous pregnancy. Compare with secondary RPL women, immunological abnormalities were more common in primary RPL. However, miscarriage rates were not different. CONCLUSION: Immunological factor including autoimmune and alloimmune disorders was most common etiology of RPL. Inherited thrombophilia showed different patterns with other ethnic countries. Miscarriage rates were not different between primary and secondary RPL, or between two and three or more miscarriages group.
Abortion, Spontaneous
;
Antibodies, Anticardiolipin
;
Antibodies, Antinuclear
;
Antibodies, Antiphospholipid
;
Antithrombin III
;
Blood Glucose
;
Chromosome Aberrations
;
Factor V
;
Female
;
Homocysteine
;
Humans
;
Killer Cells, Natural
;
Live Birth
;
Lupus Coagulation Inhibitor
;
Plasminogen Activators
;
Pregnancy
;
Pregnancy Outcome*
;
Pregnancy*
;
Prolactin
;
Protein C
;
Protein S
;
Thrombophilia
;
Thyrotropin